The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.
Pharmaceutical development is a long, risky, and expensive process. In this highly competitive market, pharmaceutical companies are under constant pressure to deliver innovation via new therapeutics, new technology, and improved efficiency and effectiveness (1). Precompetitive collaboration is recognized as a mechanism to enhance efficiency, mitigate risks, and share costs that can benefit industry, academia, and government agencies. For the purposes of this viewpoint, “precompetitive collaboration” may be defined as collaborations between pharmaceutical companies and third parties to produce an efficiency-enhancing advancement or refinement that will be made broadly available to the public (i.e., publication, commercialization of a new product).
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 45–49
When referring to this article, please cite it as M. M. Faul et al.,“Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation," BioPharm International Regulatory Sourcebook eBook (October 2020).
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.